Brentuximab vedotin maintenance post-ASCT for high-risk systemic ALCL (AETHERA-style, 16 cycles)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-BRENTUXIMAB-VEDOTIN |
|---|
| ID | REG-BRENTUXIMAB-MAINTENANCE-ALCL |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-PTCL-2024 SRC-NCCN-BCELL-2025 |
Notes
Adapted from AETHERA (Moskowitz 2015 cHL) — extrapolated to systemic ALCL high-risk post-autoSCT (primary refractory, relapse <12 mo, multiple lines pre-ASCT, extranodal at relapse). Strongest rationale for ALK-negative ALCL where natural history post-ASCT remains poor. ECHELON-2 follow-up data (Horwitz 2022, 5-yr) further supports BV consolidation strategies in CD30+ T-cell. Off-label in this setting per NCCN — practice-level recommendation, not registration.
Used By
Indication
IND-ALCL-MAINTENANCE-BV-POST-ASCT- IND-ALCL-MAINTENANCE-BV-POST-ASCT